This is investment research, not personal financial advice.

Nanosonics Limited (ASX:NAN) closed at A$3.05 on 25 August, down 17.1% from A$3.68, after reporting FY26 revenue of A$203.9 million and operating profit of A$16.0 million. The fall reached roughly 25% during the session. The immediate cause was not a broken trophon franchise. It was the FY27 cost map: operating expenses are expected to rise 10-15% while first-year CORIS revenue remains only in the low single-digit millions (Nanosonics results 2026; Stockhead 2026).

The result separates a working trophon franchise from an unproven CORIS launch. FY26 revenue rose 3% as reported and 6% at constant currency. Recurring consumables and service revenue rose 6%, the global installed base reached 39,700 trophon units, and North American upgrade volumes rose 30%. But group operating profit fell 10% because the CORIS segment lost A$34.6 million before commercial launch. Management then paired a more expensive launch year with a new A$40 million on-market share buyback (Nanosonics presentation 2026; Nanosonics buyback 2026).

The closing price gives a fairly stark verdict. Nanosonics' existing cash, leases and trophon segment profit imply an enterprise value equal to 15.4 times FY26 trophon EBIT. At a 15-times franchise multiple, only about A$21 million of value remains for CORIS. The 17% reaction therefore looks proportionate to the near-term earnings reset, but severe in the way it almost deletes a cleared second platform before the first 20-30 US sites report any commercial evidence.

A better result produced a worse earnings map

The FY26 release reads better backward than forward. Total trophon revenue rose 3% to A$203.9 million, or 6% at constant currency. Device sales grew 9% to 4,230 units. North American upgrade volumes reached 2,135 units, up 30%, while capital revenue rose 6% and recurring revenue rose 6%. Gross margin held at 76.9%, just 30 basis points below FY25 (Nanosonics results 2026).

Those gains did not reach group EBIT. The mature trophon operating segment generated A$50.6 million of EBIT, up 38%. CORIS incurred a A$34.6 million operating loss as Nanosonics funded regulatory work, manufacturing, the commercial team and controlled release. Group operating profit was A$16.0 million, down from A$17.8 million. Statutory net profit fell 14% to A$17.8 million, helped by A$4.1 million of net finance income on the cash balance (Nanosonics annual report 2026).

FY27 widens that split. Management expects 8-12% constant-currency revenue growth, a 74-76% gross margin and a 10-15% increase in operating expenses. The CORIS contribution is expected to be only low single-digit millions of Australian dollars because the first half is a controlled US release across 20-30 sites. Broader US commercialisation is planned for the second half. In plain arithmetic, A$220-228 million of revenue at a 74-76% gross margin yields roughly A$163-173 million of gross profit. Applying the stated cost growth to FY26's expense base leaves little room for group operating profit in the launch year.

Currency adds a second translation risk. Nanosonics reports in Australian dollars but earns most revenue in North America. The RBA's 25 August observation was US$0.7150 per Australian dollar, stronger than some of the rates that benefited prior reported revenue (RBA 2026). The constant-currency outlook may therefore convert into a lower reported growth rate if the Australian dollar remains firm.

The market did not reject FY26. It repriced the gap between a sound installed-base result and a more costly FY27 than headline revenue growth alone suggested.

trophon still funds the laboratory

Nanosonics sells infection-prevention systems into clinical workflows where failed disinfection carries patient, regulatory and reputational costs. trophon2 automates high-level disinfection of ultrasound probes. The company places capital equipment, then earns repeat revenue from proprietary consumables and service. That installed-base model matters more than any one device shipment because every active unit can produce an annuity-like stream of chemical consumables and support revenue.

The numbers still support that moat. The global installed base grew to about 39,700 units in FY26. Total placements rose 9%, recurring revenue rose 6%, and upgrades in North America rose 30%. Regulatory history adds friction for a new entrant: FDA records show clearances for the original trophon, trophon2 and related accessories, with the devices classified for specialised disinfection use (FDA 2026). Clinics also have staff training, protocols, probe compatibility and infection-control audits built around the installed system.

But this moat has limits. Nanosonics still has one material profit pool. The company reports trophon and CORIS as operating segments, yet all meaningful FY26 segment profit came from trophon. Product concentration makes the installed base valuable and fragile at the same time. A change in probe design, infection-control guidance, reimbursement or a rival workflow could hit the cash engine while CORIS is still consuming it.

The peer comparison shows what the model can become without proving that Nanosonics will get there. STERIS reported US$5.94 billion of FY26 revenue, including US$2.88 billion of service revenue and US$1.81 billion of consumables. It defines those two streams as recurring revenue. Capital equipment was US$1.25 billion, the smaller stream (STERIS 2026). Nanosonics has the same broad capital-plus-recurring logic, but not STERIS's product breadth, service scale or geographic diversification. The comparison validates the economics, not the outcome.

That is why CORIS matters. A second installed base could reduce concentration and create another proprietary consumables stream. Until there is field evidence, however, CORIS is an option funded by trophon rather than a second moat.

Five years show cash generation without a smooth return curve

The statutory record is lumpy. FY23 captured a sharp revenue and operating-profit step-up. FY24 revenue barely grew and EBIT more than halved. FY25 recovered, then FY26 revenue growth slowed while CORIS spending rose. A straight line through the endpoints would hide the operating swings.

A$m unless stated FY22 FY23 FY24 FY25 FY26
Revenue 120.3 166.0 170.0 198.6 203.9
EBIT 1.8 19.6 9.1 17.8 16.0
NPAT 3.7 19.9 13.0 20.7 17.8
Operating cash flow 6.7 23.3 22.8 44.0 22.6
Author-computed owner cash (0.3) 19.7 20.3 35.3 17.4
Author-computed ROIC 2.5% 23.2% 10.3% 21.1% 15.8%
Author-computed interest cover 3.2x 25.5x 8.3x 12.2x 9.5x

Source-reported revenue, EBIT, NPAT, operating cash flow and cash come from the respective annual reports (Nanosonics annual report 2022; Nanosonics annual report 2023; Nanosonics annual report 2024; Nanosonics annual report 2025; Nanosonics annual report 2026). Owner cash is author-computed as operating cash flow less purchases of property, plant, equipment and intangibles. It is not company-reported free cash flow. ROIC is author-computed as EBIT taxed at 30%, divided by average invested capital, where invested capital equals equity plus lease liabilities less cash. Interest cover is author-computed as EBIT divided by filed finance expense.

The five-year owner-cash total is A$92.4 million. That is a useful counterweight to the statutory volatility because all CORIS research and development expense runs through the income statement before reaching operating cash flow. It also needs care. FY25's A$35.3 million was flattered by working-capital timing, while FY26 operating cash flow fell to A$22.6 million. The lower FY26 conversion occurred even before the heaviest commercial phase of CORIS.

ROIC tells the same story. It rose above 20% in FY23 and FY25, then fell to 15.8% in FY26 as the company signed a larger head-office, manufacturing and research lease and kept funding the second platform. End-period invested capital rose from A$56.0 million to A$85.4 million in FY26, mainly because lease liabilities rose to A$23.1 million. Incremental ROIC is not meaningful across these swings: the FY23 profit step arrived before later CORIS investment, while FY26 added capital and operating cost ahead of revenue. A single incremental ratio would pretend that timing mismatch does not exist.

trophon has produced cash across a full cycle, but the group has not shown a stable return path while building CORIS.

CORIS starts with 30 sites, not a second franchise

CORIS automates internal cleaning of flexible endoscopes. FDA data records a De Novo decision in March 2025 and a subsequent 510(k) clearance in March 2026 for the CORIS System (FDA 2026). Those clearances reduce technical and regulatory uncertainty. They do not establish hospital demand, installation time, staff acceptance or consumable intensity.

The controlled release is designed to answer those questions. Nanosonics plans to place the system in 20-30 US sites in the first half of FY27, collect workflow data and refine the commercial model before a broader second-half rollout. Management says a CORIS device is priced at roughly three to five times a trophon system and could be used three to four times as often. That creates a larger theoretical recurring-revenue pool per installed unit (Nanosonics presentation 2026).

There are three unresolved mechanisms behind that claim.

First, a hospital has to move cleaning work from an existing manual or automated process into CORIS. Regulatory clearance helps the clinical argument, but budget ownership and workflow redesign still matter. Second, usage has to generate enough proprietary consumable demand to support the service and commercial infrastructure. Third, the controlled sites must be representative. A favourable result from carefully selected launch partners may not transfer to a broad hospital network.

The FY27 revenue guide keeps expectations grounded. Low single-digit millions from CORIS means the launch will not offset its cost base this year. Nanosonics is spending to gather commercial evidence, not harvesting a second installed base. The value of 20-30 sites therefore comes from information: repeat usage, time per cycle, staff retention, customer reference quality and the conversion rate into broader placements.

A strong first-half site count without repeat consumable orders would be an optical success. Conversely, a modest placement count with high utilisation and clean renewals could be more valuable than the headline number. The filed data do not yet disclose an average selling price, consumable revenue per cycle or gross margin for CORIS. Any detailed unit-economics model would fill those gaps with guesses.

The A$40 million buyback does not remove the launch bill

Nanosonics ended FY26 with A$155.2 million of cash and no bank borrowings. Lease liabilities were A$23.1 million, leaving A$132.1 million of cash less leases. It also carried A$48.1 million of contract liabilities, much of which represents service obligations that have already brought in cash. The balance sheet can fund the launch without external capital under a reasonable range of outcomes (Nanosonics annual report 2026).

The buffer is not idle. The annual report records A$15.3 million of non-cancellable inventory and manufacturing commitments, up from A$9.4 million. A ten-year Macquarie Park lease added a A$17.7 million right-of-use asset and A$17.7 million lease liability. Management paid A$20 million under the previous on-market buyback and has now announced a further program of up to A$40 million (Nanosonics annual report 2026; Nanosonics buyback 2026).

If the new program were completed immediately at A$3.05, it would use about a quarter of year-end cash. In valuation terms, repurchasing shares at the market price is close to neutral before transaction costs: cash falls, but so does the share count. The economic question is whether the cash has a higher return inside CORIS, inside trophon, or returned through fewer shares. That cannot be answered from the buyback announcement alone because management has not disclosed a hurdle rate for the program.

The timing creates tension. FY27 is the year of maximum evidence gathering and limited CORIS revenue, while management is committing capital to reduce the share count. The balance sheet can support both today. The monitoring threshold is whether cash less leases stays above A$100 million after the program and launch spending. Below that level, the company would still be liquid, but the margin for a slow rollout or another product program would be materially smaller.

Capital allocation has otherwise been conservative. There is no acquisition goodwill on the balance sheet, development expenditure is expensed rather than capitalised, and the group has not used debt to manufacture return metrics. Those choices improve the quality of the accounts. They do not make the next A$40 million automatically accretive.

A$3.05 almost erases CORIS from enterprise value

A sum-of-the-parts approach fits Nanosonics better than a single earnings multiple. trophon is a profitable installed-base franchise. CORIS is a loss-making platform with regulatory clearance but almost no commercial revenue. Applying one group multiple to FY27 trough earnings would value launch spending as if it were permanent, while applying a mature growth multiple to CORIS would assume the very adoption that remains unproven.

At A$3.05 and 298.911 million shares, equity value is A$911.7 million. Subtracting cash less leases of A$132.1 million gives an enterprise value of A$779.6 million. That equals 15.4 times FY26 trophon segment EBIT of A$50.6 million. Put another way, a 15-times value for trophon leaves about A$20.6 million for CORIS and other net effects. A 12-times trophon value leaves A$172 million; an 18-times value implies negative A$131 million for everything else.

The table holds FY26 trophon EBIT at A$50.6 million and cash less leases at A$132.1 million. It varies the franchise multiple and the amount assigned to CORIS. All outputs are author estimates per current share.

CORIS option value 12x trophon EBIT 15x 18x 21x
A$0m A$2.47 A$2.98 A$3.49 A$4.00
A$150m A$2.98 A$3.48 A$3.99 A$4.50
A$300m A$3.48 A$3.98 A$4.49 A$5.00
A$500m A$4.15 A$4.65 A$5.16 A$5.67

The post-result price sits close to the A$2.98 combination of a 15-times trophon franchise and no CORIS option value. That reverse valuation is the central finding. It shows what has to change the story without pretending that an early-stage platform can be modelled to the nearest cent.

FY26 author-computed owner cash was A$17.4 million, producing a 52-times price-to-owner-cash ratio. On that measure the shares are not priced as a conventional low-growth industrial. The apparent cheapness exists only if trophon's segment economics can be separated from temporary CORIS spending and if some of that spending creates future value.

Four paths depend on adoption, not spreadsheet precision

The scenario ranges use the same sum-of-the-parts structure. Each combines a trophon EBIT range and franchise multiple, a separate CORIS option value and a net-cash range. They are valuation maps, not forecasts or target prices.

Case Operating frame Value per share
Severe downside trophon EBIT A$42-46m at 11-13x; CORIS A$0-25m; net cash A$100-130m A$1.88-A$2.52
Bear trophon EBIT A$46-52m at 13-15x; CORIS A$0-100m; net cash A$105-135m A$2.35-A$3.40
Base trophon EBIT A$52-60m at 16-19x; CORIS A$150-350m; net cash A$100-140m A$3.62-A$5.45
Bull trophon EBIT A$60-70m at 19-22x; CORIS A$400-700m; net cash A$120-160m A$5.55-A$8.03

The severe case assumes the installed-base franchise weakens while launch spending fails to establish CORIS. It is the only case in which both sides of the portfolio disappoint together. The bear case is less dramatic: trophon remains profitable, but CORIS has little demonstrated value and the franchise multiple stays near the post-result level.

The base case requires more than meeting the 20-site floor. It assumes repeat CORIS usage produces a credible consumables stream, allowing the market to assign A$150-350 million to the platform before full scale. trophon also has to move beyond FY26's A$50.6 million segment EBIT. The bull case needs broad commercial conversion, not just controlled-release placements, plus a higher multiple for the existing franchise.

Two variables dominate the range. Every three turns of trophon EBIT multiple adds about A$0.51 per share at the FY26 segment result. Every A$150 million assigned to CORIS adds about A$0.50 per share. That symmetry explains the violence of the 25 August move. A change in either the mature-franchise multiple or the launch option can move the equity by roughly half a dollar.

The anti-thesis is hidden in recurring revenue

The strongest case against the market's reaction is the part of the result that did not break. The installed base grew, recurring revenue grew, upgrades accelerated and gross margin stayed near 77%. Nanosonics has no bank debt, expenses development work and now has FDA-cleared products in two infection-prevention categories. If CORIS adoption arrives on schedule, the current enterprise value leaves little explicit room for that second platform.

The strongest case in favour of the reaction is timing. FY27 cost growth is expected to exceed constant-currency revenue growth, reported growth faces an Australian-dollar headwind, and CORIS contributes little revenue during the year. The same company that is asking investors to tolerate a profit valley has announced another A$40 million buyback. A 39,700-unit trophon base also means future growth depends increasingly on upgrades, underpenetrated geographies and usage, rather than the easy arithmetic of building from a small base.

The 17.1% fall is broadly proportionate to the disclosed FY27 earnings pressure. The closing valuation is less neutral: it values trophon at a mid-teens segment EBIT multiple and assigns almost nothing to CORIS. That can prove too harsh, but only field evidence can do the proving.

H1 FY27 is the first hard checkpoint

The crux has two parts. The first is commercial. By the February 2027 half-year result, Nanosonics should be able to report whether the controlled US release reached 20-30 CORIS sites, how frequently they used the system and whether consumable demand repeated. Fewer than 20 sites would indicate installation or adoption friction. Site count without utilisation would leave the economics unanswered.

The second is financial. Constant-currency revenue growth below 8%, gross margin below 74% or operating-cost growth above 15% would each widen the launch valley beyond the FY26 plan. Cash less leases falling below A$100 million after the buyback would not create a solvency problem, but it would show that capital returns and evidence gathering are consuming flexibility faster than the current valuation bridge assumes.

Source notes and confidence

Confidence is high on the FY26 accounts, market move, regulatory history and announced launch plan. The Finance API sidecar resolved the ASX identity but its latest daily bar stopped on 20 August, so the 25 August close and move were reconciled to the ASX issuer page and Google Finance instead. Confidence is lower on CORIS unit economics because the company has not disclosed device average selling price, consumable revenue per procedure, customer acquisition cost or platform gross margin. Those missing numbers are the point of the controlled release.

At A$3.05, the market is pricing a profitable trophon franchise and treating CORIS as a claim that has not yet earned capitalised value. The next edition of this story will be written by site utilisation, not another laboratory milestone.

References